KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Notes Payables (2016 - 2025)

Gsk (GSK) has 8 years of Notes Payables data on record, last reported at $3.0 billion in Q4 2024.

  • For Q4 2024, Notes Payables fell 13.24% year-over-year to $3.0 billion; the TTM value through Dec 2024 reached $3.0 billion, down 13.24%, while the annual FY2024 figure was $3.0 billion, 13.78% down from the prior year.
  • Notes Payables reached $3.0 billion in Q4 2024 per GSK's latest filing, down from $3.5 billion in the prior quarter.
  • Across five years, Notes Payables topped out at $4.9 billion in Q4 2021 and bottomed at $3.0 billion in Q4 2024.
  • Average Notes Payables over 4 years is $4.0 billion, with a median of $4.1 billion recorded in 2022.
  • Peak YoY movement for Notes Payables: fell 4.51% in 2022, then dropped 25.03% in 2023.
  • A 4-year view of Notes Payables shows it stood at $4.9 billion in 2021, then decreased by 4.51% to $4.6 billion in 2022, then decreased by 25.03% to $3.5 billion in 2023, then dropped by 13.24% to $3.0 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $3.0 billion in Q4 2024, $3.5 billion in Q4 2023, and $4.6 billion in Q4 2022.